Culbertson A N & Co. Inc. Buys 185 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Culbertson A N & Co. Inc. increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,998 shares of the medical equipment provider’s stock after buying an additional 185 shares during the period. Culbertson A N & Co. Inc.’s holdings in Zimmer Biomet were worth $634,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dunhill Financial LLC grew its position in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet in the 3rd quarter valued at $28,000. Bangor Savings Bank bought a new position in Zimmer Biomet during the 3rd quarter worth $31,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet during the third quarter worth $35,000. Finally, Quarry LP bought a new stake in shares of Zimmer Biomet in the second quarter valued at about $53,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $109.65 on Tuesday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $100.67 and a fifty-two week high of $133.90. The stock has a market cap of $21.83 billion, a PE ratio of 20.85, a PEG ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The firm’s fifty day moving average price is $107.84 and its two-hundred day moving average price is $108.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the company posted $1.65 EPS. Zimmer Biomet’s quarterly revenue was up 4.1% compared to the same quarter last year. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Wall Street Analyst Weigh In

ZBH has been the subject of several analyst reports. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Oppenheimer dropped their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Royal Bank of Canada increased their price target on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Finally, Evercore ISI reduced their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $123.33.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.